Developer docs
API playgroundTry for free, no card

Search company profiles

Labiotech.eu

Full company profile

uuid0009ab2

Namestring
Labiotech.eu
Legal namestring
Labiotech UG (haftungsbeschränkt)
Websiteurl
labiotech.eu
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Labiotech.eu is a Berlin-headquartered B2B digital media company that has operated since 2014 as a specialized publisher covering the European biotechnology industry. The platform delivers editorial coverage of biotech funding, clinical trials, partnerships, regulatory developments, and therapeutic-area advances through daily news articles, in-depth features, expert commentary, and the Beyond Biotech Podcast. Underlying technology is a web-based editorial CMS with podcast distribution infrastructure (Apple Music, Spotify, Buzzsprout), email newsletter delivery, and a growing set of structured knowledge-hub resources including dedicated trackers for biotech funding, deals, layoffs, and events. Labiotech.eu serves four primary segments: biotech and biopharma companies, investors and financial professionals tracking deal flow, life sciences researchers and academics, and large pharmaceutical firms monitoring the innovation landscape. Customer concentrations extend across EMEA and into the US market. The company operates as Labiotech UG (haftungsbeschränkt), a German private limited company, and is a subsidiary of Inpart.

Short descriptiontext

Labiotech.eu is a Berlin-based B2B digital media publisher covering the European biotech industry since 2014. It serves biotech companies, investors, researchers, and pharma firms via daily editorial, the Beyond Biotech Podcast, knowledge-hub trackers, and newsletters, monetized through advertising, sponsored content, and subscriptions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech news media, life sciences reporting, biopharma industry coverage, biotech industry analysis, biotech editorial content
Industry1 code
PRIMARYEDAGAGAG
Scientific & Laboratory Reference (Chemistry, Biology, Physics; Methods & Protocols)
Education/Educational Publishing & Learning Content/Professional & Technical Reference Publishing
SIC code1 code
  • Periodicals: Publishing Or Publishing & Printing2721
Product category
Biotech Industry Digital Media
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Advertising and Sponsored Content
TypeAdvertising
Description

Labiotech.eu generates revenue primarily through sponsored articles, advertising placements, and sponsored content partnerships with biotech companies, CDMOs, pharmaceutical companies, and industry service providers. Companies like Cryoport Systems, Lonza, Lexogen, and ICEX-Invest in Spain advertise through the platform.

labiotech.eu
2Subscription/Premium Content
TypeSubscription Recurring
Description

The platform offers premium content behind paywalls, requiring users to subscribe for full access. The website indicates locked content that requires subscription to continue reading, suggesting a freemium or subscription model for certain in-depth articles.

labiotech.eu
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Marketing or Sales, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeDigital Commerce or Conte…
Digital Commerce or Content
Core offering1 text field

Labiotech.eu is a B2B digital media platform covering the European biotechnology industry. It publishes daily news articles, in-depth features, industry analysis, podcasts, and newsletters aimed at biotech professionals, investors, and pharma companies, and monetizes through advertising and sponsored content. It also operates tracking tools for biotech funding, deals, layoffs, events, grants, and associations as part of its "Knowledge Hub" resource offering.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Labiotech.eu is Europe's leading biotech news platform offering a unified content ecosystem with news articles, in-depth analysis, podcasts, and specialized knowledge hub tools. The core product is the news platform itself, supplemented by the Beyond Biotech Podcast series, and complemented by tracking tools for biotech funding, deals, and layoffs, plus resources for biotech events, grants, and associations. The newsletter provides email-based content delivery. All offerings function together as a comprehensive information resource for the global life sciences community.

Product and service4 records
1Labiotech.eu News Platform
CategoryDigital Media / Editorial News
Description

A web-based biotech industry news platform delivering editorial articles, in-depth features, and expert opinion pieces on biotechnology topics including funding, clinical trials, partnerships, M&A, and regulatory developments for biotech and life sciences professionals.

2Beyond Biotech Podcast
CategoryPodcast / Audio Content
Description

A podcast series covering biotech industry topics with interviews of industry leaders and discussions on emerging trends, technologies, and companies in the life sciences sector; distributed via Apple Music, Spotify, and Buzzsprout.

3Labiotech Newsletter
CategoryEmail Newsletter / Content Delivery
Description

A recurring email newsletter that delivers the latest biotech industry news, funding updates, and analysis directly to subscribers' inboxes, driving engagement and return visits.

4Sponsored Content and Advertising
CategoryAdvertising / Sponsored Content
Description

A B2B advertising and sponsored content offering that allows biotech companies, CDMOs, and pharmaceutical firms to place sponsored articles and advertising on Labiotech.eu for access to its life sciences audience.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Inpart is the parent company of Labiotech.eu. The partnership involves content collaboration including the 'Biotech Perspective' report series and referral traffic through Inpart's network connecting accelerators, startups, academia, and investors with biotech companies for collaborative opportunities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioSpace is a leading digital media platform covering the biotech and pharmaceutical industries with news, job listings, and industry intelligence. It is directly comparable as a B2B biotech news and careers destination serving the same biotech professional audience as Labiotech, though with a stronger US focus.

TypeDirect peer
Description

Endpoints News is a digital biotech news publication founded by veteran journalist John Carroll covering drug development, biotech business, and industry deals. It is directly comparable to Labiotech as a daily B2B biotech news outlet monetized through subscriptions and advertising targeting biotech and pharma professionals.

TypeDirect peer
Description

Fierce Biotech is a long-established biotech industry news brand within the Fierce Pharma network, covering R&D, clinical trials, manufacturing, and business news. It competes directly with Labiotech for pharma and biotech readership and advertising dollars, though it operates as part of a broader B2B media portfolio.

TypeDirect peer
Description

BioCentury is a subscription-based B2B intelligence provider covering biotech strategy, business, and science for investors and pharma BD teams. It is directly comparable to Labiotech in audience (biotech investors, pharma executives) and product model (deep industry coverage plus proprietary analysis), with a stronger paywalled subscription business.

TypeDirect peer
Description

GEN is a long-running biotech industry publication covering drug discovery, bioprocessing, omics, and translational research. It is comparable to Labiotech as a multi-format B2B biotech media outlet serving scientists, biotech executives, and investors with news and analysis.

TypeDirect peer
Description

BioWorld is a subscription-based biotech news and intelligence service owned by Clarivate, covering clinical trials, regulatory, and business developments. It directly competes with Labiotech in serving biotech and pharma professionals with paid news intelligence, though it is part of a much larger data analytics parent.

TypeBroad incumbent
Description

Drug Discovery & Development is an industry publication covering drug R&D, lab technology, and translational research. It is comparable to Labiotech in covering biotech R&D topics, but operates more as a general industry trade outlet under the Informa/Informa Markets portfolio rather than a focused daily news brand.

TypeBroad incumbent
Description

MedCity News covers healthcare innovation, digital health, biotech, and life sciences investing. It overlaps with Labiotech in biotech business and funding coverage but extends to broader healthcare and digital health topics, making it a broader-incumbent peer rather than a direct biotech-specialist.

TypeEmerging player
Description

Bio-IT World covers the intersection of informatics, computing, and biotechnology, including AI in drug discovery and clinical research. It is comparable to Labiotech in covering emerging biotech technology themes but with a narrower specialization in the informatics and computational biology niche.

10BioPharma Reporter
TypeEmerging player
Description

BioPharma Reporter covers biopharmaceutical manufacturing, processing, and industry business developments. It shares biotech industry news coverage with Labiotech but with a manufacturing and bioprocessing specialization, making it an adjacent rather than direct competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Labiotech.eu

Biotech Industry Digital Medialabiotech.eu

Labiotech.eu is a Berlin-based B2B digital media publisher covering the European biotech industry since 2014. It serves biotech companies, investors, researchers, and pharma firms via daily editorial, the Beyond Biotech Podcast, knowledge-hub trackers, and newsletters, monetized through advertising, sponsored content, and subscriptions.

What Labiotech.eu does

Labiotech.eu is a Berlin-headquartered B2B digital media company that has operated since 2014 as a specialized publisher covering the European biotechnology industry. The platform delivers editorial coverage of biotech funding, clinical trials, partnerships, regulatory developments, and therapeutic-area advances through daily news articles, in-depth features, expert commentary, and the Beyond Biotech Podcast. Underlying technology is a web-based editorial CMS with podcast distribution infrastructure (Apple Music, Spotify, Buzzsprout), email newsletter delivery, and a growing set of structured knowledge-hub resources including dedicated trackers for biotech funding, deals, layoffs, and events. Labiotech.eu serves four primary segments: biotech and biopharma companies, investors and financial professionals tracking deal flow, life sciences researchers and academics, and large pharmaceutical firms monitoring the innovation landscape. Customer concentrations extend across EMEA and into the US market. The company operates as Labiotech UG (haftungsbeschränkt), a German private limited company, and is a subsidiary of Inpart.

Labiotech.eu firmographics

Firmographics
Name
Labiotech.eu
Legal name
Labiotech UG (haftungsbeschränkt)
Website
https://labiotech.eu
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Labiotech.eu is a Berlin-based B2B digital media publisher covering the European biotech industry since 2014. It serves biotech companies, investors, researchers, and pharma firms via daily editorial, the Beyond Biotech Podcast, knowledge-hub trackers, and newsletters, monetized through advertising, sponsored content, and subscriptions.
Ownership category
akta.pro rank

Labiotech.eu industry classification

Industry
Product category
Biotech Industry Digital Media
SIC
Periodicals: Publishing Or Publishing & Printing (2721)
akta.pro industry
PRIMARYEDAGAGAG
Scientific & Laboratory Reference (Chemistry, Biology, Physics; Methods & Protocols)
Education/Educational Publishing & Learning Content/Professional & Technical Reference Publishing

Keywords

  • Biotech news media
  • Life sciences reporting
  • Biopharma industry coverage
  • Biotech industry analysis
  • Biotech editorial content

Where Labiotech.eu is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Labiotech.eu business model

Business model
GTM type
B2B
Offering type
Digital Commerce or Content
Cost components
Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

  1. Advertising and Sponsored Content: Labiotech.eu generates revenue primarily through sponsored articles, advertising placements, and sponsored content partnerships with biotech companies, CDMOs, pharmaceutical companies, and industry service providers. Companies like Cryoport Systems, Lonza, Lexogen, and ICEX-Invest in Spain advertise through the platform.
  2. Subscription/Premium Content: The platform offers premium content behind paywalls, requiring users to subscribe for full access. The website indicates locked content that requires subscription to continue reading, suggesting a freemium or subscription model for certain in-depth articles.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Labiotech.eu product offering

Product offering

Core offering

Labiotech.eu is a B2B digital media platform covering the European biotechnology industry. It publishes daily news articles, in-depth features, industry analysis, podcasts, and newsletters aimed at biotech professionals, investors, and pharma companies, and monetizes through advertising and sponsored content. It also operates tracking tools for biotech funding, deals, layoffs, events, grants, and associations as part of its "Knowledge Hub" resource offering.

Product overview

Labiotech.eu is Europe's leading biotech news platform offering a unified content ecosystem with news articles, in-depth analysis, podcasts, and specialized knowledge hub tools. The core product is the news platform itself, supplemented by the Beyond Biotech Podcast series, and complemented by tracking tools for biotech funding, deals, and layoffs, plus resources for biotech events, grants, and associations. The newsletter provides email-based content delivery. All offerings function together as a comprehensive information resource for the global life sciences community.

Differentiator

Problem solved

Functional benefit

Products and services

  • Labiotech.eu News Platform A web-based biotech industry news platform delivering editorial articles, in-depth features, and expert opinion pieces on biotechnology topics including funding, clinical trials, partnerships, M&A, and regulatory developments for biotech and life sciences professionals.
  • Beyond Biotech Podcast A podcast series covering biotech industry topics with interviews of industry leaders and discussions on emerging trends, technologies, and companies in the life sciences sector; distributed via Apple Music, Spotify, and Buzzsprout.
  • Labiotech Newsletter A recurring email newsletter that delivers the latest biotech industry news, funding updates, and analysis directly to subscribers' inboxes, driving engagement and return visits.
  • Sponsored Content and Advertising A B2B advertising and sponsored content offering that allows biotech companies, CDMOs, and pharmaceutical firms to place sponsored articles and advertising on Labiotech.eu for access to its life sciences audience.

Companies that use Labiotech.eu

Customer profile

Segments4 records

Ideal customer profiles4 records

Labiotech.eu technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Labiotech.eu partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • InpartcoreStrategic or Co-development PartnerInpart is the parent company of Labiotech.eu. The partnership involves content collaboration including the 'Biotech Perspective' report series and referral traffic through Inpart's network connecting accelerators, startups, academia, and investors with biotech companies for collaborative opportunities.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Labiotech.eu competitors and assessment

Company assessment

Direct peers

  • BioSpace: BioSpace is a leading digital media platform covering the biotech and pharmaceutical industries with news, job listings, and industry intelligence. It is directly comparable as a B2B biotech news and careers destination serving the same biotech professional audience as Labiotech, though with a stronger US focus.
  • Endpoints News: Endpoints News is a digital biotech news publication founded by veteran journalist John Carroll covering drug development, biotech business, and industry deals. It is directly comparable to Labiotech as a daily B2B biotech news outlet monetized through subscriptions and advertising targeting biotech and pharma professionals.
  • Fierce Biotech: Fierce Biotech is a long-established biotech industry news brand within the Fierce Pharma network, covering R&D, clinical trials, manufacturing, and business news. It competes directly with Labiotech for pharma and biotech readership and advertising dollars, though it operates as part of a broader B2B media portfolio.
  • BioCentury: BioCentury is a subscription-based B2B intelligence provider covering biotech strategy, business, and science for investors and pharma BD teams. It is directly comparable to Labiotech in audience (biotech investors, pharma executives) and product model (deep industry coverage plus proprietary analysis), with a stronger paywalled subscription business.
  • Genetic Engineering & Biotechnology News (GEN): GEN is a long-running biotech industry publication covering drug discovery, bioprocessing, omics, and translational research. It is comparable to Labiotech as a multi-format B2B biotech media outlet serving scientists, biotech executives, and investors with news and analysis.
  • BioWorld (Clarivate): BioWorld is a subscription-based biotech news and intelligence service owned by Clarivate, covering clinical trials, regulatory, and business developments. It directly competes with Labiotech in serving biotech and pharma professionals with paid news intelligence, though it is part of a much larger data analytics parent.

Broad incumbents

  • Drug Discovery & Development: Drug Discovery & Development is an industry publication covering drug R&D, lab technology, and translational research. It is comparable to Labiotech in covering biotech R&D topics, but operates more as a general industry trade outlet under the Informa/Informa Markets portfolio rather than a focused daily news brand.
  • MedCity News: MedCity News covers healthcare innovation, digital health, biotech, and life sciences investing. It overlaps with Labiotech in biotech business and funding coverage but extends to broader healthcare and digital health topics, making it a broader-incumbent peer rather than a direct biotech-specialist.

Emerging players

  • Bio-IT World: Bio-IT World covers the intersection of informatics, computing, and biotechnology, including AI in drug discovery and clinical research. It is comparable to Labiotech in covering emerging biotech technology themes but with a narrower specialization in the informatics and computational biology niche.
  • BioPharma Reporter: BioPharma Reporter covers biopharmaceutical manufacturing, processing, and industry business developments. It shares biotech industry news coverage with Labiotech but with a manufacturing and bioprocessing specialization, making it an adjacent rather than direct competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Labiotech.eu social profiles

Digital presence

Labiotech.eu financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Labiotech.eu leadership team

Management profile

Number of profiles

Profiles1 record

Labiotech.eu funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Labiotech.eu M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Labiotech.eu

What does Labiotech.eu do?

Labiotech.eu is a B2B digital media platform covering the European biotechnology industry. It publishes daily news articles, in-depth features, industry analysis, podcasts, and newsletters aimed at biotech professionals, investors, and pharma companies, and monetizes through advertising and sponsored content. It also operates tracking tools for biotech funding, deals, layoffs, events, grants, and associations as part of its "Knowledge Hub" resource offering.

Is Labiotech.eu a public or private company?

Labiotech.eu is a private company. It is classified as corporate owned and is currently operating.

When was Labiotech.eu founded?

Labiotech.eu was founded in 2014. It employs 11 to 50 people.

Where is Labiotech.eu based?

Labiotech.eu is headquartered in Berlin, Germany, in the Europe region.

How does Labiotech.eu make money?

Two revenue lines are on record. Advertising and Sponsored Content is the primary driver. The others are subscription/Premium Content.

Who are Labiotech.eu's main competitors?

Direct peers on record are BioSpace, Endpoints News, Fierce Biotech, BioCentury, Genetic Engineering & Biotechnology News (GEN) and BioWorld (Clarivate). Broad incumbents are Drug Discovery & Development and MedCity News. Emerging players are Bio-IT World and BioPharma Reporter.

Does Labiotech.eu have an API?

No public API is recorded for Labiotech.eu.

What industry is Labiotech.eu in?

Labiotech.eu's product category is Biotech Industry Digital Media. Its primary akta.pro industry code is EDAGAGAG, Scientific & Laboratory Reference (Chemistry, Biology, Physics; Methods & Protocols). Its SIC code is 2721.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Labiotech.euWe asked, you answered: Labiotech’s 2026 reader survey resultsLabiotech published the results of its 2026 reader survey, revealing that its audience is predominantly senior decision-makers in the biotech sector with strong engagement from Europe and North America. The report highlights high satisfaction rates and identifies key content preferences, including a demand for new formats like infographics and short videos, as well as expanded coverage in therapeutic areas such as oncology and cell therapy. Based on this feedback, Labiotech announced plans to introduce new digital events, monthly market series, and improved platform features to better serve its community.Labiotech.euWe asked, you answered: Labiotech’s 2026 reader survey resultsLabiotech surveyed its newsletter subscribers and found over 80% are senior decision-makers, with more than 80% engaging weekly. Oncology and cell therapy lead reader interest, and the newsletter is the top format. The company plans new formats, expanded events, and a preclinical assets series.LoomlyMeet the Future Makers of LabiotechLabiotech welcomed three new hires: Jim Cornall as Editor-in-Chief, Omnia Ibrahim as Editor, and Alban Whandja as Sales Manager. The team expansion follows the company's acquisition by Inova. The interview covers their backgrounds and advice for science communication careers.LoomlyLabiotech.eu Is Being Acquired by InovaInova, a biopharma partnering platform, acquired Labiotech.eu. Labiotech will remain editorially independent, with Inova providing resources for content. Future plans will be announced in coming months.Labiotech.euLabiotech.eu Is Being Acquired by InovaInova, a biopharma partnering platform provider, has acquired Labiotech.eu. The acquisition aims to combine Inova's software tools with Labiotech's media presence to offer an integrated space for managing partnerships and staying informed in the life sciences sector.